Dr. Bill Williams, BriaCell’s President and CEO, called into SmallCapVoice.com to discuss the recent news and events for the Company here in the summer of 2021. BriaCell is expanding its breast cancer platform technology into other cancers including prostate, melanoma, and non-small cell lung cancer. Bria-OTS™, an off-the-shelf personalized immunotherapy for advanced breast cancer, remains on track to enter the clinic in 2021. In addition, BCTX announced the open recruitment and enrollment of their collaborative clinical study with Incyte. The Phase I/IIa combination study is designed to evaluate BriaCell’s lead candidate, Bria-IMT™, with Incyte’s checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, for the treatment of advanced breast cancer.
“We are thrilled about the prospects of our novel targeted off-the-shelf personalized immunotherapies for patients with advanced prostate cancer, melanoma and lung cancer,” said Dr. Bill Williams, BriaCell’s President & CEO. “Working with our world class scientists and collaborators, we look forward to bring these novel immunotherapies to patients in desperate need of new treatments.”
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.